Skip to content

PolitiKit

Mark Vineis's lobbying: the registrations they file and every meeting they've reported since November 2021.

← Lobbying

Registrant (responsible officer)

Mark Vineis

Country President

For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.

Meetings this Parliament
15
Since Nov 2021
35
Active registrations
0

Reported meetings

  • Novartis Pharmaceuticals Canada Inc.
    • Mahamat Djalal · Director of Policy, Quebec, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Shawn Boyle · Chief of Staff, House of Commons
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Marie-Christine Demers · Senior Policy Advisor, Natural Resources Canada (NRCan)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more

    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Meron Cheway · Director of Operations, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more

    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Evan Solomon · Minister of AI and Digital Innovation, Innovation, Science and Economic Development Canada (ISED)
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Phillip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Free trade agreements as they relate to biomanufacturing industry in Canada

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Bryce McRae · Manager of Stakeholder Relations, House of Commons
    • Andrew Evans · Manager of Stakeholder Relations, House of Commons
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Greg Orenscsak · Deputy Minister, Health Canada (HC)
    • Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB) Read more

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Mary Ng · Minister of International Trade, Global Affairs Canada (GAC)
    • Niloo Boroun · Director of Policy, Global Affairs Canada (GAC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Aaron Wudrick · Director of Policy, House of Commons

    HealthIndustry

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    HealthIndustry

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Valerie Bradford · Member of Parliament, House of Commons

    HealthIndustry

    Official report

  • Novartis Pharmaceuticals Canada Inc.

    HealthIndustry

    Official report

  • Novartis Pharmaceuticals Canada Inc.

    HealthIndustry

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.